XyloCor’s cardiovascular gene therapy XC001 passes Phase 1 with promising results
XyloCor Therapeutics, Inc., a company specializing in the development of gene therapies for cardiovascular diseases, announced that the Phase 1 findings of its clinical trial (EXACT) for XC001 (encoberminogene rezmadenovec) have been published in the journal Circulation: Cardiovascular Interventions. The trial results are promising, revealing that XC001 is well-tolerated at all dose levels for patients […]